G. Kirk Raab will be racking up the frequent flyer miles. After being named chairman of Shaman Pharmaceuticals Inc. in September, he has now accepted the same post at Oxford GlycoSystems Ltd. half a world away in Abingdon, U.K.

Raab's deal with OGS is structured along the same lines as his commitment at SHMN, which is to play a more active role than the average chairman or board member (see BioCentury, Sept. 18). He expects to be at OGS at least six times a year, and the company will hold some of its board meetings in the U.S.